Biwalentne ligandy receptorów opioidowych

• Autorzy: Frączak O. , Olma A.

Warianty tytułu

EN

Bivalent ligands of opioid receptors

• Języki publikacji: PL

Abstrakty

EN

Opioids are the oldest drugs know to humanity, which have been and continue to be used for the treatment of chronic pain. Unfortunately they have a large numbers of side effects [1–6]. Three main types of opioid receptors μ (MOR), δ (DOR) and κ (KOR) are known [8]. The ORL1 receptor was classified as the fourth member of opioid receptor family [9]. Opioid receptors can form homodimers and the following heterodimers: DOR-KOR, DOR-MOR and KOR-MOR [13c,d,f, 14]. Specially designed ligands which are able to penetrate the BBB are used to study physiological consequences of opioid receptor homo- and heterodimerization, and as new analgesics. Bivalent ligands are defined as compounds that contain two pharmacophoric units, an appropriately designed spacer to separate and define the two pharmacophores, and a linker unit to connect the pharmacophores, to the spacer (Fig. 1) [16]. The affinity of a ligand to its target depends on its fundamental kinetic association and dissociation rate constants (Scheme 1) [24]. Bivalent ligands interacting with the opioid receptors have been divided into three groups: nonpeptide, peptide- nonpeptide and peptide homo- or heterodimers. Nonpeptide bivalent ligands (4–21, 27–41 and 44–45) containing different pharmacophores (selective opioid agonists or/and antagonists) connected with designed linkers have potent analgesic properties [25–34]. Compound 35 may be useful in the treatment of opioid dependence. Studies of peptide-nonpeptide ligands, which are a combination of “address” segments of endogenous opioid peptides and selective alkaloid ligand (47–50) indicate that peptide part of the analogues can modulate the receptor selectivity of the attached alkaloid pharmacophores [35]. Series of peptide-nonpeptide ligands containing different classes of opioid peptides and fentanyl (52–86) were synthesized and tested for binding affinity to μ and δ opioid receptors [38–40]. Good opioid affinity and antinociceptive activity of some of the obtained bivalent ligands (57, 61, 63) suggesting that a novel class of analgesics can be further developed utilizing this approach. Among homobivalent ligands the most important is biphalin 87 and its analogues (88–124) [41–53]. Analgesic potency of the most active ligand 112 is greater than parent peptide (biphalin) and morphine.

Słowa kluczowe

PL

peptydy opioidowe; biwalentne ligandy niepeptydowe; biwalentne ligandy peptydowe; aktywność opioidowa; homobiwalentne ligandy; heterobiwalentne ligandy

EN

opioid peptides; nonpeptide bivalent ligands; peptide bivalent ligands; opioid activity; homobivalent ligands; heterobivalent ligands

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2014
• Tom: [Z] 68, 3-4
• Strony: 233--255
• Opis fizyczny: Bibliogr. 55 poz., schem., tab.

Twórcy

autor

Frączak O.

• Instytut Chemii Organicznej, Wydział Chemiczny, Politechnika Łódzka ul. Żeromskiego 116, 90-924 Łódź

autor

Olma A.

• Instytut Chemii Organicznej, Wydział Chemiczny, Politechnika Łódzka ul. Żeromskiego 116, 90-924 Łódź

Bibliografia

• [1] X. Ruan, Pain Phys., 2007, 10, 357.
• [2] (a) T. Dzierżanowski, J. Jarosz, Onkol. Prak. Klin., 2009, 5, 47. (b) P. Holzer, Eur. Rev. Med., Pharmacol. Sci., 2008, 12, 119. (c) F. Porreca, M. Ossipov, Pain Medicine, 2009, 10, 654.
• [3] C. Pasero, J. Perianesth. Nurs., 2009, 24, 186.
• [4] (a) S. Silverman, Pain Physician, 2009, 12, 679. (b) L. Chu, D. Clark, M. Angs, J. Pain, 2006, 7, 43.
• [5] R. Abs, J. Verhelst, J. Maeyaert, J. Buyten, F. Opsomer, H. Adriaensen, J. Verlooy, T. Havenbergh, M. Smet, K. Acker, J. Clin. Endocrinol. Metab., 2000, 85, 2215.
• [6] (a) S. Jan, J. Manag. Care Pharm., 2010, 16, 4. (b) H. Adriaensen, K. Vissers, H. Noorduin, T. Meert, Acta Anaesth. Belg., 2003, 54, 37.
• [7] B. Cox, A. Borsodi, G. Calo, C. Chavkin, M. Christie, O. Civelli, L. Devi, C. Evans, G. Henderson, V. Hollt, B. Kieffer, I. Kitchen, M. Kreek, L. Liu-Chen, J. Meunier, P. Portoghese, T. Shippenberg, E. Simon, L. Toll, J. Traynor, H. Ueda, Y. Wong, Opioid receptors. [online], IUPHAR database (IUPHAR-DB), [dostęp: 2013-11-26]. Dostępny w Internecie: http://www.iuphar-db.org/DATABASE/FamilyMenuForward? familyId=50.
• [8] B. Dhawan, F. Cesselin, R. Raghubir, T. Reisine, P. Bradley, P. Portoghese, M. Hamon, Pharmacol. Rev., 1996, 48, 567.
• [9] C. Mollereau, M. Parmentier, P. Mailleux, J. Butour, C. Moisand, P. Chalon, D. Caput, G. Vassart, J. Meunier, FEBS Lett., 1994, 341, 33.
• [10] (a) L. Chiou, Y. Liao, P. Fan, P. Kuo, C. Wang, C. Riemer, E. Prinssen, Curr. Drug Targets, 2007, 8, 117. (b) M. Connor, M. Christie, Clin. Exp. Pharmacol. Physiol., 1999, 26, 493.
• [11] (a) B. Kieffer, K. Befort, C. Gaveriaux-Ruff, C. Hirth, Proc. Natl. Acad. Sci. USA, 1992, 89, 12048. (b) S. Li, J. Zhu, C. Chen, Y. Chen, J. Deriel, B. Ashby, L. Liu-Chen, Biochem. J., 1993, 295, 629. (c) Y. Chen, A. Mestek, J. Liu, L. Yu, Biochem. J., 1993, 295, 625.
• [12] (a) C. Hiller, J. Kuhhorn, P. Gmeiner, J. Med. Chem., 2013, 56, 6542. (b) B. Levac, B. O’Dowd, R. George, Curr. Opin. Pharmacol., 2002, 2, 76. (c) C. Hiller, J. Kuhhorn, P. Gmeiner, J. Med. Chem., 2013, 56, 6542.
• [13] (a) S. Angers, A. Salahpour, M. Bouvier, Annu. Rev. Pharmacol. Toxicol., 2002, 42, 409. (b) C. Rios, B. Jordan, I. Gomes, L. Devi, Pharmacol. Ther., 2001, 92, 71. (c) I. Gomes, B. Jordan, A. Gupta, N. Trapaidze, V. Nagy, L. Devi, J. Neurosci., 2000, 20, 1. (d) P. Portoghese, M. Lunzer, Eur. J. Pharmacol., 2003, 467, 233. (e) B. Jordan, L. Devi, Nature, 1999, 399, 697. (f) D. Wang, X. Sun, L. Bohn, W. Sadee, Mol. Pharmacol., 2005, 67, 2173.
• [14] S. George, T. Fan, Z. Xie, R. Tse, V. Tam, G. Varghese, B. O’Dowd, J. Biol. Chem., 2000, 275, 26128.
• [15] S. Ballet, M. Pietsch, A. Abell, Protein Peptide Lett., 2008, 15, 668-682.
• [16] J. Shonberg, P. Scammells, B. Capuano, Chem. Med. Chem., 2011, 6, 963.
• [17] J. Soulier, O. Russo, M. Giner, L. Rivali, M. Berthouze, S. Ongeri, B. Maigret, R. Fischmeister, F. Lezoualch, S. Sicsic, I. Berque-Bestel, J. Med. Chem., 2005, 48, 6220.
• [18] K. Jacobson, P. Galen, M. Williams, J. Med. Chem., 1992, 35, 407.
• [19] P. Karellas, M. McNaughton, S. Bakern, P. Scammells, J. Med. Chem., 2008, 51, 6128.
• [20] Y. Zheng, E. Akgu, K. Harikumar, I. Hopson, M. Powers, M. Lunzer, L. Miller, P. Portoghese, J. Med. Chem. 2009, 52, 247.
• [21] P. Portoghese, J. Med Chem., 2001, 44, 2259.
• [22] (a) R. Bhushan, S. Sharma, Z. Xie, D. Daniels, P. Portoghese, J. Med. Chem., 2004, 47, 2969. (b) S. Zhang, A. Yekkirala, Y. Tang, P. Portoghese, Bioorg. Med. Chem. Lett., 2009, 19, 6978.
• [23] M. Weber, A. Bujotzek, R. Haag, J. Chem. Phys., 2012, 137, 1.
• [24] G. Vauquelin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 2013, 386, 949.
• [25] M. Erez, A. Takemori, P. Portoghese, J. Med. Chem., 1982, 25, 841.
• [26] (a) P. Portoghese, G. Ronsisvalle, D. Lamon, A. Takemori, J. Med. Chem., 1986, 29, 1650. (b) P. Portoghese, D. Larson, C. Yim, L. Sayre, G. Ronsisvalle, A. Lipkowski, A. Takemori, K. Rice, S. Tam, J. Med. Chem., 1985, 28, 1140. (c) P. Portoghese, D. Larson, L. Sayre, C. Yim, G. Ronsisvalle, S. Tam, A. Takemori, J. Med. Chem., 1986, 29, 1855.
• [27] (a) P. Portoghese, H. Nagase, A. Lipkowski, D. Larson, A. Takemori, J. Med. Chem., 1988, 31, 836. (b) P. Portoghese, A. Garzon-Aburbeh, H. Nagase, C. Lin, A. Takemori, J. Med. Chem., 1991, 34, 1292. (c) P. Portoghese, J. Med. Chem., 1992, 35, 1927.
• [28] (a) S. Archer, A. Seyed-Mozaffari, Q. Jiang, J. Bidlack, J. Med. Chem., 1994, 37, 1578. (b) S. Archer, S. Glick, I. Maisonneuve, J. Bidlack, J. Xu, M. Teitler, A. Sebastian, W. El-Hamouly, I. Hutchinson, Bioorg. Med. Chem. Lett., 1996, 6, 1139. (c) S. Archer, S. Glick, J. Bidlack, Neurochem. Res., 1996, 21, 1369.
• [29] (a) J. Neumeyer, A. Zhang, W. Xiong, X. Gu, J. Hilbert, B. Knapp, S. Negus, N. Mello, J. Bidlack, J. Med. Chem., 2003, 46, 5162. (b) J. Mathews, X. Peng, W. Xiong, A. Zhang, S. Negus, J. Neumeyer, J. Bidlack, J. Pharmacol. Exp. Ther., 2005, 315, 821. (c) X. Peng, B. Knapp, J. Bidlack, J. Neumeyer, J. Med. Chem., 2006, 49, 256. (d) X. Peng, B. Knapp, J. Bidlack, J. Neumeyer, J. Med. Chem., 2007, 50, 2254. (e) M. Decker, B. Fulton, B. Zhang, B. Knapp, J. Bidlack, J. Neumeyer, J. Med. Chem., 2009, 52, 7389. (f) B. Fulton, B. Knapp, J. Bidlack, J. Neumeyer, Bioorg. Med. Chem. Lett., 2010, 20, 1507. (g) B. Zhang, T. Zhang, A. Sromek, T. Scrimale, J. Bidlack, J. Neumeyer, Bioorg. Med. Chem. 2011, 19, 2808.
• [30] R. Jones, P. Portoghese, Eur. J. Pharmacol., 2000, 396, 49.
• [31] D. Daniels, A. Kulkarni, Z. Xie, R. Bhushan, P. Portoghese, J. Med. Chem., 2005, 48, 1713.
• [32] (a) D. Daniels, N. Lenard, C.Etienne, P. Law, S. Roerig, P. Portoghese, PNAS, 2005, 102, 19208. (b) N. Lenard, D. Daniels, P. Portoghese, S. Roerig, Eur. J. Pharmacol., 2007, 566, 75. (c) M. Aceto, L. Harris, S. Negus, M. Banks, L. Hughes, E. Akgun, P. Portoghese, Int. J. Med. Chem., 2012, ID 327257, 6 pages. (d) A. Yekkirala, A. Kalyuzhny, P. Portoghese, ACS Chem. Biol., 2013, 8, 1412.
• [33] J. Harvey, D. Long, P. England, J. Whistler, ACS Med. Chem. Lett., 2012, 3, 640.
• [34] M. Giudice, A. Borioni, G. Bastanzio, M. Sbraccia, C. Mustazza, I. Sestili, Eur. J. Med. Chem., 2011, 46, 1207.
• [35] A. Lipkowski, S. Tam, P. Portoghese, J. Med. Chem., 1986, 29, 1222.
• [36] P. Portoghese, D. Larson, G. Ronsisvalle, P. Schiller, T. Nguyen, C. Lemieux, A. Takemori, J. Med. Chem., 1987, 30, 1991.
• [37] J. Neumeyer, X. Peng, B. Knapp, J. Bidlack, L. Lazarus, S. Salvadori, C. Trapella, G. Balboni, J. Med. Chem., 2006, 49, 5640.
• [38] Y. Lee, J. Nyberg, S. Moye, R. Agnes, P. Davis, S. Ma, J. Lai, F. Porreca, R. Vardanyan, V. Hruby, Bioorg. Med. Chem. Lett., 2007, 17, 2161.
• [39] (a) Lee Y., R. Petrov, C. Park, S. Ma, P. Davis, J. Lai, F. Porreca, R. Vardanyan, V. Hruby, J. Med. Chem., 2007, 50, 5528. (b) Y. Lee, V. Kulkarani, S. Cowell, S. Ma, P. Davis, K. Hanlon, T. Vanderah, J. Lai, F. Porreca, R. Vardanyan, V. Hruby, J. Med. Chem., 2011, 54, 382.
• [40] (a) R. Petrov, R. Vardanyan, Y. Lee, S. Ma, P. Davis, L. Begay, J. Lai, F. Porreca, V. Hruby, Bioorg. Med. Chem. Lett., 2006, 16, 4946. (b) R. Petrov, Y. Lee, R. Vardanyan, L. Liu, S. Ma, P. Davis, J. Lai, F. Porreca, T. Vanderah, V. Hruby, Bioorg. Med. Chem. Lett., 2013, 23, 3434.
• [41] (a) A. Lipkowski, A. Konecka, I. Sroczyńska, Peptides, 1982, 3, 697. (b) F. Feliciani, F. Pinnen, A. Stefanucci, R. Costante, I. Cacciatore, G. Lucente, A. Mollica, Mini-Rev. Med. Chem., 2013, 13, 11.
• [42] (a) B. Silbert, A. Lipkowski, M. Cepeda, S. Szyfelbein, P. Osgood, D. Carr, Agents Actions, 1991, 33, 382. (b) P. Horan, A. Mattie, E. Bilsky, S. Weber, T. Davis, H. Yamamura, E. Malatynska, S. Appleyard, J. Slaninova, A. Misicka, A. Lipkowski, V. Hruby, F. Porreca, J. Pharmacol. Exp. Ther., 1993, 265, 1446.
• [43] M. Yamazaki, T. Suzuki, M. Narita, A. Lipkowski, Life Sci., 2001, 69, 1023.
• [44] (a) A. Lipkowski, A. Konecka, I. Sroczyńska, R. Przewłocki, L. Stala, S. Tam, Life Sci., 1987, 40, 2283. (b) A. Misicka, A. Lipkowski, R. Horvath, P. Davis, T. Kramer, H. Yamamura, V. Hruby, Life Sci., 1992, 51, 1025.
• [45] A. Misicka, A. Lipkowski, R. Horvath, P. Davis, F. Porreca, H. Yamamura, V. Hruby, Life Sci., 1997, 60, 1263.
• [46] G. Li, W. Haq, L. Xiang, B. Lou, R. Hughes, I. Leon, P. Davis, T. Gillespie, M. Romanowski, X. Zhu, A. Misicka, A. Lipkowski, F. Porreca, T. Davis, H. Yamamura, D. O’Brien, V. Hruby, Bioorg. Med. Chem., 1998, 8, 555.
• [47] (a) A. Lipkowski, A. Misicka, P. Davis, D. Stropova, J. Janders, M. Lachwa, F. Porreca, H. Yamamura, V. Hruby, Bioorg. Med. Chem. Lett., 1999, 9, 2763. (b) A. Lipkowski, A. Misicka, D. Kosson, P. Kosson, M. Lachwa-From, A. Brodzik-Bienkowska, V. Hruby, Life Sci., 2002, 70, 893.
• [48] A. Mollica, P. Davis, S. Ma, F. Porreca, J. Lai, V. Hruby, Bioorg. Med. Chem. Lett., 2006, 16, 367.
• [49] (a) A. Mollica, F. Pinnen, R. Costante, M. Locatelli, A. Stefanucci, S. Pieretti, P. Davis, J. Lai, D. Rankin, F. Porreca, V. Hruby, J. Med. Chem., 2013, 56, 3419. (b) O. Frączak, A. Lasota, D. Podwysocka, A. Olma, A. Leśniak, A. Lipkowski. Dostępny w Internecie: http://21pps. umb.edu.pl/conference_book_ suprasl_2011.pdf.
• [50] J. Stepinski, I. Zajaczkowski, D. Kazem-Bek, A. Temeriusz, A. Lipkowski, S. Tam, Int. J. Pept. Protein Res., 1991, 38, 588.
• [51] A. Mollica, P. Davis, S. Ma, J. Lai, F. Porreca, V. Hruby, Bioorg. Med. Chem. Lett., 2005, 15, 2471.
• [52] A. Mollica, F. Pinnen, F. Feliciani, F. Stefanucci, G. Lucente, P. Davis, F. Porreca, S. Ma, J. Lai, V. Hruby, Amino Acids, 2011, 40, 1503.
• [53] (a) S. Leone, A. Chiavaroli, G. Orlando, A. Mollica, C. Nisio, L. Brunetti, M. Vacca, Eur. J. Pharmacol., 2012, 685, 70. (b) A. Mollica, R. Costante, A. Stefanucci, F. Pinnen, G. Lucente, S. Fidanzad, S. Pieretti, J. Pept. Sci., 2013, 19, 233.
• [54] L. Lazarus, A. Guglietta, W. Wilson, B. Irons, R. Castiglione, J. Biol. Chem., 1989, 264, 354.
• [55] (a) Y. Jinsmaa, A. Miyazaki, Y. Fujita, T. Li, Y. Fujisawa, K. Shiotani, Y. Tsuda, T. Yokoi, A. Ambo, Y. Sasaki, S. Bryant, L. Lazarus, Y. Okada, J. Med. Chem., 2004, 47, 2599. (b) T. Li, Y. Fujita, K. Shiotani, A. Miyazaki, Y. Tsuda, A. Ambo, Y. Sasaki, Y. Jinsmaa, E. Marczak, S. Bryant, S. Salvadori, L. Lazarus, Y. Okada, J. Med. Chem., 2005, 48, 8035.